We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
I am also actively involved in the Pediatric Translational Medicine Program we are developing at Memorial Sloan Kettering. Through this program, we use new technologies to gather information about the biology and genetics of each patient’s tumor. That information helps guide treatment decisions, and we can use it to create new treatments that specifically target an individual’s cancer. Our goal is not only to cure more children, teens, and young adults but to improve our patients’ quality of life by reducing the side effects that traditional treatments can cause.
Read more
I work with research groups at MSK and others across the nation (through the Children’s Oncology Group) to develop and use laboratory models to learn more about the biology of various cancers. These models are genetic replicas of a patient’s tumor. They allow us to identify and test new treatments without having to involve the patient. I am also involved in leading clinical trials of new treatments for cancer, particularly pediatric sarcomas.
The diagnosis and treatment of cancer can create an unimaginably difficult journey for children, teens, and young adults, as well as their parents and caregivers. I continue to be inspired by the relationships among these families as they face these challenges together. It is my job to make sure they know that we are here to guide them through treatment, and that we will provide world-class care to achieve the best possible outcome.
My Role at MSK
A pediatric hematologist-oncologist is a doctor who treats cancers and blood diseases in children, adolescents and young adults.
Areas of Expertise
My Specialties
Pediatric Sarcomas
Ewing sarcoma
Osteosarcoma
Rhabdomyosarcoma
Desmoplastic Small Round Cell Tumor
Education & Honors
Education
MD, University of California, Davis
Residencies
University of California, San Francisco
Fellowships
Columbia University Medical Center
Board Certifications
Pediatrics
Pediatric Hematology/Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
Aetna
In Network Coverage Type HMO, EPO PPO, POS, Transplant
Request an appointment by logging on to MyMSK or calling your doctor’s office. If you aren’t registered for MyMSK, call 646-227-2593 for your Enrollment ID.
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. Tannenbaum-Dvir S, Glade Bender JL, Church AJ, Janeway KA, Harris MH, Mansukhani MM, Nagy PL, Andrews SJ, Murty VV, Kadenhe-Chiweshe A, Connolly EP, Kung AL, Dela Cruz FS. Cold Spring Harbor molecular case studies. 2015; 1(1):a000471.
A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Dela Cruz FS, Diolaiti D, Turk AT, Rainey AR, Ambesi-Impiombato A, Andrews SJ, Mansukhani MM, Nagy PL, Alvarez MJ, Califano A, Forouhar F, Modzelewski B, Mitchell CM, Yamashiro DJ, Marks LJ, Bender JL, Kung AL. Genome medicine. 2016; 8(1):116.
Publications on PubMed
Visit PubMed for a full listing of Dr. Dela Cruz’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
We strive to keep reviews trustworthy, honest and fair.
Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Filemon Dela Cruz discloses the following relationships and financial interests:
Biosplice Therapeutics Professional Services and Activities (Uncompensated)
Daiichi Sankyo Professional Services and Activities (Uncompensated)
Day One Biopharmaceuticals, Inc. Professional Services and Activities (Uncompensated)
Eisai Professional Services and Activities (Uncompensated)
Jazz Pharmaceuticals Professional Services and Activities (Uncompensated)
Kronos Bio, Inc Professional Services and Activities (Uncompensated)
Sanofi US Services Inc. Professional Services and Activities (Uncompensated)
Shasqi Professional Services and Activities (Uncompensated)
Y-mAbs Therapeutics, Inc. Professional Services and Activities (Uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.
